Dataset Information

ISPI: A Multi-dimensional, Regenerable, Proteome-scale, Human Phosphopeptide Resource for Phosphoproteomics

ABSTRACT: Mass spectrometry-based phosphoproteomics has become indispensable for understanding cellular signaling in complex biological systems. Despite the central role of protein phosphorylation, the field still lacks inexpensive, regenerable, and diverse phosphopeptides with ground truth phosphorylation positions that can serve as gold standards for method development and pipeline evaluation. Here, we present Iterative Synthetically Phosphorylated Isomers (iSPI), a proteome-scale library of human-derived phosphoserine-containing phosphopeptides produced in E. coli using the phosphoserine orthogonal translation system. Because phosphoserine is genetically encoded, the position of phosphorylation is precisely known. Since the library is synthesized in E. coli, phosphopeptide production is scalable and regenerable. We demonstrate the utility of iSPI as a phosphopeptide standard to investigate instrument acquisition methods, to evaluate and optimize phosphorylation site localization algorithms, and to compare performance across data analysis pipelines. As a direct result of iSPI analyses, we present AscorePro, an updated version of the Ascore algorithm that has been specifically optimized for localization of phosphorylation sites in higher energy fragmentation spectra. In addition, we provide the FLR Viewer for Phosphorylation Site Localization, a browser-based tool allowing the community to calculate phosphorylation site false localization rates using their own workflows and analysis pipelines. Thus, iSPI and its associated data constitute a useful, multi-dimensional resource for the phosphoproteomics community.

INSTRUMENT(S): Orbitrap Eclipse

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Brandon Gassaway

LAB HEAD: Steven Gygi

PROVIDER: PXD031171 | Pride | 2022-10-26

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 54

Publications

A multi-purpose, regenerable, proteome-scale, human phosphoserine resource for phosphoproteomics.

Gassaway Brandon M BM Li Jiaming J Rad Ramin R Mintseris Julian J Mohler Kyle K Levy Tyler T Aguiar Mike M Beausoleil Sean A SA Paulo Joao A JA Rinehart Jesse J Huttlin Edward L EL Gygi Steven P SP

Nature methods 20221024 11

Mass-spectrometry-based phosphoproteomics has become indispensable for understanding cellular signaling in complex biological systems. Despite the central role of protein phosphorylation, the field still lacks inexpensive, regenerable, and diverse phosphopeptides with ground-truth phosphorylation positions. Here, we present Iterative Synthetically Phosphorylated Isomers (iSPI), a proteome-scale library of human-derived phosphoserine-containing phosphopeptides that is inexpensive, regenerable, an ...[more]

PMID: 36280721

Similar Datasets

Project description:Type 2 diabetes (T2D) is major cause of mortality and morbidity. The key manifestations of this disease are insulin resistance (IR), hyperglycemia and hyperinsulinemia. Secretion of insulin from the endocrine pancreas is triggered by elevated circulating glucose and acts on skeletal muscle and adipose tissues to remove excess glucose from the blood (1). This is achieved through a series of intracellular events that trigger the translocation of vesicles containing the glucose transporter 4 (GLUT4) to the surface of skeletal muscle cells and adipocytes (2,3). This process is impaired in patients with IR or T2D and insulin fails to promote GLUT4 translocation, thus resulting in inefficient glucose uptake in storage tissue and hyperglycemia (4). Chronic hyperglycemic condition increases the risk of cardiovascular disease, stroke, neuropathy, and death (5). Previously developed insulin sensitizer like thiazolidinediones (TZDs) have proven effective in improving glycemic control, however, they significantly increase the risk of cardiovascular disease due to their agonist activity at PPAR(6-8). Consequently, identifying insulin sensitizers that restore insulin-stimulated GLUT4 translocation in diabetic patients without targeting PPAR is urgently needed. The discovery of such molecules has been challenging due to the lack of a GLUT4 translocation assay amenable to high throughput screening (HTS). For this reason, we have developed a new luminescence based HTS assay that allows real time monitoring of GLUT4 translocation in mammalian cells and further adapted the assay to measure GLUT4 translocation in live mice. Using this assay, we identified a new insulin sensitizer which greatly improves insulin-dependent glucose uptake in storage tissues and glucose tolerance in insulin resistant rodents. This new insulin sensitizers acts through interaction with the Unc119 family of proteins which are known to facilitate the transport of specific cargos (9) but had not yet been implicated in insulin action or GLUT4 translocation. This study identifies new PPAR-independent insulin sensitizers with in-vivo efficacy and identify Unc119 proteins as new targets for the treatment of T2D.

			Action	DRS
	ea06329.mzIdentML	Mzid
	ea06329.mzXML	Mzxml
	ea06329.raw	Raw
	ea06330.mzIdentML	Mzid
	ea06330.mzXML	Mzxml